Background: Recent extensive clinical evidence demonstrated that autologous adult stem cell therapy was safe and effective as a treatment strategy for type 1 diabetes. Our initial work was designed to examine the safety and efficacy of the implantation technique on 20 subjects with six months of evolution. This new report ana-lyzes the results from three years follow up.
Methods: With the authorization from the Minis-try of Health of Argentina, 20 subjects with type 1 diabetes were treated with single autologous bone marrow cell transplantation into pancreatic blood flow through pancreatic artery catheteri-zation immediately after bone marrow aspiration. The primary endpoint was defined as normaliza-tion of C-peptide and glycated hemoglobin (Hb-A1c) with insulin independence at 3 years post-treatment. Results: 15 subjects (75%) achieved clinical improvements. 7 subjects (33%) reached the primary endpoint, in which 4 subjets with decreased C-peptide levels required insulin ad-ministration again at 3 years post-treatment. Other 8 subjects (34%) showed partial function at 3 years post-treatment. There were no serious adverse events observed. No increases of islet cell antibody (ICA) and glutamic acid decarb-oxylase (GAD) antibody.
Conclusion: This pro-cedure may be a safe and effective treatment for chronic type 1 diabetes. The follow-up results showed a significant increase of the pancreatic secretion of C-peptide and a decrease in the daily dose of exogenous insulin. This effect par-tially disappears by the three years follow-up without an increase of the level of the ICA and GAD antibodies.
Copyright © 2005-2015 北科生物 All Rights Reserved 粤ICP备15094023号-1